

China Pharmaceutical & Biotechnology Monthly

March 2009

Tracking China Healthcare

Vol. 24

Animal Attraction

The past year has been a particularly eventful one for pre-clinical contract research organizations (CROs) in China. An area that had been slow to develop compared to other CRO service offerings, the preclinical contract research space has witnessed a rapid increase in the scale and quality of services offered. What was once only a handful of local government and/or academic animal labs has developed into a growing sector comprised of multiple domestic and multinational players

pursuing a variety of business and partnership models. As shrinking biotechnology research budgets and big pharma mergers curb demand, at least in the short term, for outsourcing preclinical services, the sector may be in store for lean times. GBI takes a look at the current status of CROs in China offering preclinical animal testing, and considers some possible winners and losers that will emerge from the challenging period going forward.

[Continued on page 2](#)

Inside This Month:

Partial list of contents

Top Stories P1

Animal Attraction

Protection of Pharmaceutical IP in China

Drawing Stimulus

Sheldon Dorenfest on H.I.T.

Key Facts and Figures P18

2008 MOH Healthcare Statistics

Deals P20

Notable deals announced during the month of March

Product Watch P21

SFDA approvals for unique drug applications in March

General P22

MOF director: central government public health budget to be RMB 118B for 2009

Policy & Regulations P28

Chongqing institutes prescription fees, will eliminate drug markups

Investment & Finance P33

Hubei Wushi and Hubei Beike to build RMB 1 billion peds drug production base

J&J, Janssen, and Yabang-QH establish API production facility

Earnings P37

2008 annual financial results released through end of March 2009

Company P39

Lilly CEO: Reform shapes company's plan to expand into rural regions

Schering-Plough to provide pandemic flu vaccine technology to WHO

Product & Pipeline P45

AOBO initiates P1 trial of botanical drug in US for urinary incontinence

Birth control meets girth control? Bayer brings Yasmin to China

Research & Development P47

All Hans on board: MOST funds genome-wide association study

Hospital P48

Shanghai hospitals adopt universal medical cards, records for self-pay patients

WHO, Huilongguan Hospital collaborate on suicide prevention center

Research Highlights /50

March 2009 Publications

People /51

Sheldon Dorenfest, Chief Executive Officer, The Dorenfest Group
Fang Guo, Principal Investigator, Laboratory of Targeted Cancer Therapy, SIBS

Company Profile /52

Shanghai Fosun Pharmaceutical (Group)

Equity Market Review /56

Shanghai A
Shenzhen A
HK / SINGAPORE
NYSE / NASDAQ

Events /60

April - May 2009